Phase II HDM-SPIRE Safety and Efficacy Study

PHASE2CompletedINTERVENTIONAL
Enrollment

715

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

April 13, 2017

Study Completion Date

April 13, 2017

Conditions
Rhinoconjunctivitis
Interventions
DRUG

HDM-SPIRE

1 dose every 4 weeks

DRUG

Placebo

1 dose every 4 weeks

Trial Locations (98)

Unknown

Birmingham

Huntington Beach

Long Beach

Mission Viejo

Napa

Orange

Redwood City

Rolling Hills Estates

Roseville

San Diego

Walnut Creek

Waterbury

Tallahassee

Tampa

Stockbridge

Normal

Shiloh

Evansville

Iowa City

Owensboro

Bangor

Bethesda

Gaithersburg

Brockton

Minneapolis

Plymouth

St Louis

Bellevue

Ocean City

Teaneck

Verona

Rochester

Rockville Centre

Asheville

High Point

Canton

Cincinnati

Tulsa

Medford

Portland

Bethlehem

Blue Bell

Pittsburgh

Providence

Dallas

Kerrville

Plano

San Antonio

South Burlington

Henrico

Bellingham

Seattle

Vancouver

Greenfield

Madison

Milwaukee

Hamilton

London

Niagara

Ottawa

Toronto

Windsor

Montreal

Québec

Saint Romuald

Trois-Rivières

Reims

Gironde

Bas Rhin

Meurthe-et-Moselle

Heidelberg

Essen

Goch

Dresden

Berlin

Hamburg

Ancona

Genova

Milan

Parma

Pavia

Roma

Siena

Almere Stad

Amsterdam

Beek

Durban

eMkhomazi

Ottawa

Cape Town

Sabadell

Santander

Girona

Donostia / San Sebastian

Pamplona

Bilbao

Barcelona

Seville

All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Circassia Limited

INDUSTRY

NCT02150343 - Phase II HDM-SPIRE Safety and Efficacy Study | Biotech Hunter | Biotech Hunter